Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Cellvera
Deal Size : $10.0 million
Deal Type : Agreement
Details : Under the agreement, Aditxt expands its portfolio to include innovative therapies for infectious diseases by including Avigan (favipiravir), an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase.
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
April 20, 2023
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Cellvera
Deal Size : $10.0 million
Deal Type : Agreement
Lead Product(s) : ADI-100
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI™-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.
Product Name : ADI-100
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : ADI-100
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $20.0 million
Deal Type : Public Offering
Aditxt Announces Pricing of $20.0 Million Public Offering
Details : The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
September 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $20.0 million
Deal Type : Public Offering
Lead Product(s) : ADI-100
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.
Product Name : ADI-100
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 07, 2022
Lead Product(s) : ADI-100
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable